


## VALUATION MULTIPLES

**Forward EV / EBITDA Multiples** (monthly to 12/12/2022) Source: FactSet Research Systems Inc.

Multiples in the Healthcare sector have increased over the period. At the end of November, the sector traded on a forward EV / EBITDA multiple of 8.7x, compared to the ASX200 on 8.4x.



**Average Values and Trading Multiples** (values as at 12/12/2022) Source: FactSet Research Systems Inc.

Subsector	Enterprise Value (\$ m)	EV/EBITDA FY2022	EV/EBIT FY2022	Price / Earnings FY2022
Aged Care	741	6.8x	10.5x	25.5x
Animal Health	153	5.8x	9.1x	11.1x
Biotech	139,192	21.5x	25.9x	38.0x
Hospitals & Clinics	45,576	9.8x	15.4x	21.0x
Medical Devices	1,566	NA	NA	187.9x
<b>Healthcare</b>	<b>188,312</b>	<b>4.4x</b>	<b>16.9x</b>	<b>39.4x</b>

Note: Multiples are based on the forward year of the unreported period, which for the majority of companies in the sector is FY2023. Difference in forward EV/EBITDA multiples between Figure and Table are representative of the timing difference between month-end result, and current day result. Composition of companies in Sector Dashboards are updated every 6 months. Most recent update: April 2022.

<sup>1</sup> The InterFinancial Healthcare Index set is an unweighted index comprising Healthcare sector related companies trading on the Australian Securities Exchange (ASX). Estimates are sourced from FactSet Research Systems Inc.

## MERGER & ACQUISITION NEWS...

### HILLHOUSE

 George Clinical

Value: AUD 200m (rumored)

**Hillhouse Investment Management**, the venture capital firm is to acquire a majority stake in **George Clinical**, the Australia based provider of trial management services, pharmaceutical, medical device and biotech clinical research services. The terms of the deal were undisclosed. The transaction is subject to FIRB approval.

 nexus  
Your Local World Class Hospital

 MONTERRAT  
—DAY HOSPITALS—

Value: AUD 138.6m

**Nexus Day Hospitals Holdings**, the Australia based private hospital partnership and chain operator of day hospitals performing ophthalmology, endoscopy, plastic surgery, orthopaedics, general surgery, dental surgery and other procedures, is to acquire **Montserrat Healthcare**, the local hospital operator from **Healius**, the local provider of pathology and diagnostic imaging services, and operator of medical centres.

 NEXTCAPITAL

 KCare  
Healthcare Solutions

Value: AUD 161.6m

**Next Capital**, the Australia based private equity firm is to acquire a majority stake in **K Care**, the local company engaged in the manufacturing and distribution of rehabilitation, mobility and hospital equipment.



PARTNERED HEALTH  
MEDICAL CENTRES

 fuel your life  
A DIETITIAN COMPANY

Value: Not Disclosed

**Partnered Health**, the Australia based health clinic has acquired **Fuel Your Life**, the local company engaged in in-clinic, at home and telehealth consultations. The terms of the deal were undisclosed.

 Pacific  
PRIVATE HOSPITAL

Value: AUD 10m

**Lemeurice**, the Australia based investment firm is to acquire an undisclosed stake in **Pacific 2021 Topco G**, the local private hospital.

 iMedX

RapidCare

Value: Not Disclosed

**Rapid Care Transcription**, the Singapore based holding company having interest in medical software developers, has acquired **iMedX Australia**, the Australia-based medical software developer, from **iMedX**, the United States based medical software technology company. The terms of the deal were undisclosed.

LINDEN<sup>7</sup>

 LifeStyles

Value: Undisclosed

**Linden**, the US based private equity firm, has acquired **Lifestyles Healthcare**, the Australia based sexual health and wellness business, from **Humanwell Healthcare**, the China based manufacturer of pharmaceutical medicine, such as anesthetic, central nerve system medicine, anti-infection drugs and over the counter medicine. The terms of the deal were undisclosed.

## UNDER THE MICROSCOPE...

---

- **Hough Consolidated** has agreed to acquire **Ellume**, an Australia-based rapid test maker, out of administration for USD 38m. Ellume's administrator, FTI Consulting, signed a deal with Hough, which remains subject to a vote by creditors. Hough will continue to run Ellume in Australia and the US and retain its employees following the transaction.
- **Vaxxas**, an Australia-based clinical-stage biotechnology company commercializing a novel vaccination platform, has raised USD 23m (AUD 34m) in new funds led by existing investors **OneVentures** and **UniQuest**. New investors include members of the Vaxxas Board of Directors, management team, and a number of individual investors. Proceeds from the financing will be used to advance Vaxxas' clinical programs.
- **Consolidated Financial Holdings [ASX:CWL]** has signed a conditional share purchase agreement to acquire **Amplify Eyecare**, an Australian optometry chain. The company's plans for the future growth also include further acquisitions.
- **Sonic Healthcare [ASX:SHL]**, an Australian medical diagnostics provider, has agreed to acquire a 19.99% stake in **Microba Life Sciences [ASX:MAP]**, an Australian precision microbiome company, for AUD 17.8m (USD 11.8m). Sonic is also seeking to acquire options for a further 5% stake in Microba. Exercise of the options by Sonic would result in a further investment of AUD 7.5m in Microba.
- **PolyNovo [ASX:PNV]**, an Australian developer of regenerative products for burns and wounds, is exploring opportunities to accelerate its diversification into other areas such as podiatry, skin repair (including plastic and reconstructive surgery) and outpatient and wound care clinics. The AUD 1.3bn (USD 877m) market cap company is seeing record revenue growth from sales of its NovoSorb BTM (Biodegradable TempORIZING Matrix) technology in the burns and wounds space and is now well positioned to pursue opportunities for this platform technology in other products and geographies.
- **Novotech Health**, an Australian clinical services provider, is actively working on four acquisitions with two to be closed in 2022. One of these deals is the acquisition of a European CRO and is due to be announced in the coming weeks. The Sydney-based company is reported to be in talks to acquire Poland-based **EastHORN Clinical Services** for an undisclosed amount. EastHORN's estimated annual revenue is currently USD 66.8m per year.
- **Telix Pharmaceuticals [ASX:TLX]**, a commercial-stage Australian developer of diagnostic and therapeutic (theranostic) radiopharmaceuticals, is on the lookout for more acquisitions to support its M&A strategy. The AUD 2.3bn (USD 1.5bn) market cap Melbourne-headquartered company has acquired **Optimal Tracers**, a provider of radiochemistry process development services and research tracers for clinical trials, from Sacramento, Northern California-based PET Imaging Center for an undisclosed sum.
- **Paragon Care [ASX:PGC]**, an Australian supplier of medical equipment, devices, and consumables, is looking at acquisition opportunities both in Asia and Australia. It has the internal capacity to identify and scout for targets but would also look at opportunities presented by advisors. The AUD 229.7m (USD 152.5m)-market cap company, currently with a footprint in Thailand, South Korea, Vietnam, the Philippines, China, Indonesia, Japan, Singapore, and Malaysia, is assessing various opportunities in the region to fill gaps or grow its presence.

## CONTACT DETAILS

If you are interested in specific information regarding mergers and acquisitions in the Healthcare sector, please contact David Hassum or Michael Kakanis.

Name	Position	Phone	Email
Sharon Doyle	Executive Chair	(07) 3218 9122	<a href="mailto:sdoyle@interfinancial.com.au">sdoyle@interfinancial.com.au</a>
Paul Keehan	Non-Executive Director	(07) 3218 9100	<a href="mailto:pkeehan@interfinancial.com.au">pkeehan@interfinancial.com.au</a>
Anne-Marie Birkill	Non-Executive Director	(07) 3218 9100	
Rhyll Gardner	Non-Executive Director	(07) 3218 9100	
Brad Shaw	Chief Executive Officer	(07) 3218 9100	<a href="mailto:bshaw@interfinancial.com.au">bshaw@interfinancial.com.au</a>
Mark Steinhardt	Director – M&A	(07) 3218 9105	<a href="mailto:msteinhardt@interfinancial.com.au">msteinhardt@interfinancial.com.au</a>
David Hassum	Director	(07) 3218 9108	<a href="mailto:dhassum@interfinancial.com.au">dhassum@interfinancial.com.au</a>
Andrew Wheeler	Director	(07) 3218 9107	<a href="mailto:awheeler@interfinancial.com.au">awheeler@interfinancial.com.au</a>
Graeme McKellar	Director	(07) 3218 9100	<a href="mailto:gmckellar@interfinancial.com.au">gmckellar@interfinancial.com.au</a>
Michael Kakanis	Associate Director	(07) 3218 9106	<a href="mailto:mkakanis@interfinancial.com.au">mkakanis@interfinancial.com.au</a>
Anuk Manchanda	Associate Director	(07) 3218 9100	<a href="mailto:amanchanda@interfinancial.com.au">amanchanda@interfinancial.com.au</a>
Nimerta Kumari	Associate Director	(07) 3218 9100	<a href="mailto:nkumari@interfinancial.com.au">nkumari@interfinancial.com.au</a>
Maggie Liu	Associate	(07) 3218 9100	<a href="mailto:mliu@interfinancial.com.au">mliu@interfinancial.com.au</a>

## DISCLAIMER

This information has been sourced from the ASX, Mergermarket.com and various other public information sources. Forecasts are consensus forecasts sourced from FactSet Research Systems Inc.

**Important Disclaimer** – This may affect your legal rights: Because this document has been prepared without consideration of any specific person's financial situation, particular needs and investment objectives, a financial services licensee or investment adviser should be consulted before any investment decision is made. While this document is based on information from sources which are considered reliable, InterFinancial, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does InterFinancial accept any responsibility to inform you of any matter that subsequently comes to notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of InterFinancial. This report does not constitute advice to any person.

**Disclosure.** InterFinancial has no interest in any of the securities mentioned in this publication. However, its directors, executives or consultants may have an interest in some of the securities, directly or indirectly, which are mentioned.

*InterFinancial is a member of Clairfield International, an international corporate finance firm that provides advisory services in crossborder mergers and acquisitions. Clairfield is represented by over 400 people across 22 countries, closing over 100 transactions each year.*

InterFinancial  
Corporate Finance Limited  
ABN: 49 136 962 966  
AFSL: 341675  
Level 2, 201 Charlotte Street  
GPO Box 975  
Brisbane Queensland 4001  
(07) 3218 9100  
admin@interfinancial.com.au  
www.interfinancial.com.au

